The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Hyposensitization Therapies

Hyposensitization Therapies

Hyposensitization Therapies: A systematic approach to desensitize the immune system and reduce allergic reactions.
These therapies, also known as immunotherapy, gradually expose individuals to small, controlled amounts of allergens to build tolerance and mitigate symptoms.
PubCompare.ai leverages advanced AI to identify the most effective hyposensitization protocols from scientific literature, preprints, and patents, optimizing the treatment process for smotther and more efficient outcomes.

Most cited protocols related to «Hyposensitization Therapies»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
1-Methyl-3-isobutylxanthine Adrenergic Agents A Kinase Anchor Proteins Caveolae Caveolin 3 Cytosol Heart Ventricle Hyposensitization Therapies Isoproterenol Muscle Cells Phosphodiesterase Inhibitors Phosphorylation Proteins Tissue, Membrane
Clinical information from the subject’s electronic medical record was abstracted by the research nurses. All subjects underwent an evaluation for infertility which included a follicle-stimulating hormone (FSH) level drawn on the third day of the menstrual cycle to assess ovarian reserve. After completion of the standard infertility work-up, each subject was given an infertility diagnosis by their reproductive endocrinologist according to the Society for Assisted Reproductive Technology (SART) definitions. SART diagnoses consisted of male factor infertility which included poor semen quantity/quality; female factor infertility which included endometriosis, diminished ovarian reserve, tubal and uterine disorders; other causes and unexplained infertility.
Upon completion of the infertility evaluation, subjects underwent one of three IVF treatment protocols used at the MGH Fertility Center. The three IVF treatment protocols were: (1) Luteal phase GnRH-agonist protocol using low, regular and high-dose leuprolide (Lupron), in which pituitary desensitization was begun in the luteal phase; (2) Follicular phase GnRH-agonist/Flare protocol, in which Lupron was begun in the follicular phase on day 2 of menses at 20 units and decreased to the standard dose of five units on day 5; and (3) GnRH-antagonist protocol, in which GnRH-antagonist was begun when the lead follicle reached 14 mm in size. All cycles were preceded by a cycle of oral contraceptive pills unless contraindicated. On day 3 of induced menses, exogenous gonadotropins [FSH (Gonal-F, Follistim, Bravelle)] and/or Human Menopausal Gonadotropin [hMG (Repronex, Menopur)] were initiated. In the luteal phase GnRH-agonist protocol, Lupron dose was reduced at, or shortly after, the start of ovarian stimulation with FSH/hMG. FSH/hMG and GnRH-agonist or GnRH-antagonist was continued to the day of trigger with Human Chorionic Gonadotropin (hCG), 36 h before oocyte retrieval.
Publication 2009
Bravelle Contraceptives, Oral Diagnosis Endocrinologists Endometriosis Female Infertility Fertility Follistim Gonadorelin Gonadotropins Gonal F Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Hyposensitization Therapies Leuprolide Luteal Phase Male Infertility Menopur Menotropins Menstrual Cycle Menstrual Cycle, Proliferative Phase Menstruation Nurses Oocyte Retrieval Ovarian Follicle Ovarian Reserve Ovarian Stimulation Precipitating Factors Reproduction Repronex Semen Quality Sterility, Reproductive Treatment Protocols Uterine Diseases
Data were analysed using SPSS v16, and reliability analysis conducted with FACTOR [22 ]. The scale was factor analysed (principal factor method) and Horn's parallel analysis was run to determine the factorial structure [23 (link)]. Confirmatory analyses were also completed using AMOS17 [24 ]. Means and standard deviations were calculated across the major demographic factors and self-reported visiting. A set of percentiles was prepared across gender and major age groups. A threshold of 19 and above was adopted, as the level for which is it likely that a dental practitioner would consider using additional approaches to manage the patient such as relaxation, systematic desensitisation or pharmacological adjunct. Item frequencies were inspected for male and female samples and the ratings examined across samples to determine if individuals differ by anticipatory (i.e. contemplating a visit to the dentist the next day and sitting in the waiting room) and treatment related items using the Wilcoxon Ranks Sign test. The proportion of individuals who scored 19 and above was calculated across the demographic and behavioural variables. Cross tabulations were performed with categorical variables. Multiple logistic regression was employed to establish the independent association of demographic factors (gender, age, educational level, social class and self-reported dental visiting) on the dichotomous classification of high (≥19) and moderate to low dental anxiety (≤18). Significance level was set at the conventional 5%.
Ethical approval for the study was granted by the University of Sheffield, UK.
Full text: Click here
Publication 2009
Age Groups Dental Anxiety Dental Health Services Dentist Females Gender Hyposensitization Therapies Males Patients

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
Animals, Transgenic Axon Cells Cold Temperature Diploid Cell Egtazic Acid gluconate Glycerin Heart HEPES Hyposensitization Therapies Locus Coeruleus Magnesium Chloride Medical Devices Mesencephalon Mice, Transgenic Neurons Nicotine Perfusion Pharmaceutical Preparations Pons Potassium Pressure Striatum, Corpus
Slices were transferred to a recording chamber at 21–24°C. During recordings, the standard perfusion solution consisted of the bicarbonate-buffered solution (see above) with 1 μM strychnine and 25 μM bicuculline to block inhibitory synaptic transmission. 1 mM kynurenic acid and 0.1 mM cyclothiazide (Tocris Bioscience/R&D Systems, Minneapolis, MN) were also added to block AMPA receptor saturation and desensitization, respectively. Slices were superfused at 1–3 ml/min with this external solution. Whole-cell postsynaptic patch-clamp recordings were made from visually identified cells in the MNTB region using glass pipettes of 2–3 MΩ resistance, filled with an internal recording solution consisting of the following (in mM): 110 CsCl, 35 CsF, 10 EGTA, 10 HEPES, 2 QX-314, pH: 7.2, 315–320 mOsm. Series resistance (Rs) was compensated by up to 60% and the membrane potential was held at −60 mV. Excitatory postsynaptic potentials (EPSCs) were evoked by stimulating presynaptic axons with a bipolar stimulating electrode placed midway between the medial border of the MNTB and the midline of the brainstem. A Multiclamp 700A (Axon Instruments/Molecular Devices, Union City, CA) amplifier was used. Recordings were digitized at 20 KHz with an ITC-18 A/D converter (Instrutech, Port Washington, NY) using custom procedures (written by M.A. Xu-Friedman) in IgorPro (Wavemetrics, Lake Oswego, OR) and filtered at 8 kHz. Access resistance and leak current were monitored and experiments were rejected if either parameter changed significantly. Recordings were performed at room temperature (25°C) in Figures 1-6 and 8B and at 35°C in Figure 7 and 8C.
Publication 2013
AMPA Receptors ARID1A protein, human Axon Bicarbonates Bicuculline Brain Stem Cardiac Arrest Cells cesium chloride cyclothiazide Egtazic Acid Excitatory Postsynaptic Potentials HEPES Hyposensitization Therapies Kynurenic Acid Medical Devices Membrane Potentials Perfusion Psychological Inhibition QX-314 Strychnine Synaptic Transmission

Most recents protocols related to «Hyposensitization Therapies»

After informed consent, we collected information on the patients’ plasma allergen sIgE levels, disease duration (years), blood eosinophil counts, and whether desensitization was used. The demographic information about the study’s participants is displayed in Table 1.
Full text: Click here
Publication 2023
Allergens Eosinophil Hyposensitization Therapies Patients Plasma
AR patients were treated by sublingual administration of D. farinae drops (Changdi, produced by Zhejiang Wowu Biotechnology Co., Ltd., China). SLIT with D. farinae drops can be divided into two stages: the increasing stage and the dose maintenance stage. Children under 14 years of age used No. 1–4, among which the No. 1–3 preparation was used in the incremental phase and No. 4 preparation was used in the maintenance phase. Table 1 shows the dosage schedule of D. farinae drops for children. To administer the medication, it should be swallowed 1–3 minutes after it is under the tongue. If the number of drops is too large, it can be taken several times. Patients could eat and drink normally 5 minutes after taking the medicine. Concurrent with desensitization treatment, symptomatic drugs must be used together as needed to control symptoms. The drug regimen should follow Global Initiative for Asthma (GINA) and allergic rhinitis and its impact on asthma (ARIA), and the patient’s condition should be evaluated regularly. When the patient’s condition improves, symptomatic drugs can be used for degrading treatment.
Publication 2023
Asthma Child Hyposensitization Therapies NRG1 protein, human Patients Pharmaceutical Preparations Rhinitis, Allergic Tongue Treatment Protocols
To study the effects of agonist desensitization on channel activation, the extracellular solution contained (in mM): 127 NaCl, 3 KCl, 1 MgCl2, 10 HEPES, 2.5 CaCl2 and 10 glucose, pH 7.4 with NaOH. Osmolarity was adjusted to 310 mOsm/l with glucose. The intracellular solution contained (in mM): 135 KCl, 2 MgCl2, 2 MgATP, 5 EGTA and 10 HEPES, pH 7.4 with CsOH. Osmolarity was adjusted to 300 mOsm/l with glucose.31 (link)To study the effects of intracellular calcium in channel modulation, the extracellular solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4 with NaOH. Osmolarity was adjusted to 310 mOsm/l with glucose. The intracellular solution contained (in mM): 130 KCl, 8 NaCl, 2 EGTA, 1 MgCl2, 1 CaCl2, 4 MgATP, 0.4 Na2GTP, pH 7.4 with CsOH. Osmolarity was adjusted 300 mOsm/l with glucose.
To investigate voltage dependence, currents were recorded during a voltage-step protocol consisting of 400 ms voltage steps to test potentials ranging from −100 to +180 mV, followed by a final invariant step to −75 mV (400 ms) to measure tail currents. The holding potential was set at −0 mV.
The voltage-dependence activation of hTRPA1 p.Ala172Val in response to mustard oil [Allyl isothiocyanate (AITC) a TRPA1 electrophilic agonist] and Menthol (non-electrophilic agonist of TRPA1) was measured. These recordings were performed in a calcium-containing extracellular solution, to preserve agonist desensitization properties.33 (link) Perfusion with TRPA1 agonists was performed through a custom-made gravity perfusion system. Immediately after establishing the whole-cell configuration, perfusion was switched to extracellular solution for 2 min before beginning the voltage clamp recording. AITC (Sigma 377430) was dissolved in DMSO (Sigma D2650), and Menthol (Sigma M2772) in ethanol. The maximum final concentration of either DMSO or ethanol did not exceed 0.1%. The effect of TRPA1 agonists on current–voltage curves was measured with a two-voltage-step protocol, as described above. Voltage ramps ranging from −100 to +100 mV for 500 ms, every 5 s, were applied to elucidate the temporal activation of hTRPA1 p.Ala172Val in response to AITC. In this case, the holding potential was set at −70 mV.
Current–voltage curves (IV curves) were fitted using a combined Boltzmann and linear ohmic relationship: I/Imax = Gmax (VmErev)/(1 + exp(V1/2−Vm)/k). Normalized conductance–voltage curves (activation curves) were fitted with a Boltzmann equation G/Gmax = 1/(1 + exp(V1/2−Vm)/K), where G was calculated as follows G = I/(VmErev). Steady-state fast inactivation curves were fitted with IT/ITmax = 1/(1 + exp−(V1/2−Vm)/k). Tail current-derived voltage-activation curves were fitted to the Boltzmann equation: IT/IT (Max) = 1/(1 + exp[(Vm−V1⁄2)/k]). In all the equations, V1/2 represents the half-activation and half-inactivation membrane potentials; Vm is the membrane potential, Erev the reversal potential, k the slope factor, G the conductance and IT the current at a given Vm; Gmax and ITmax are the maximum conductance and current, respectively; Rin is the fraction of channels that are resistant to slow inactivation. Statistical significance was set at P = 0.05 for group comparisons.
Full text: Click here
Publication 2023
Adenosine Triphosphate, Magnesium Salt agonists allyl isothiocyanate Calcium Calcium Channel Cells Egtazic Acid Ethanol Glucose Gravity HEPES Hyposensitization Therapies Magnesium Chloride Membrane Potentials Menthol mustard oil Osmolarity Perfusion Protoplasm Sodium Chloride Sulfoxide, Dimethyl Tail
The intervention was held after school hours and the treatment lasted for 8 weeks (i.e., 2 months), from 5th March, 2018 to 7th May, 2018, excluding a 1 month follow-up evaluation. The intervention was delivered at a Federal College of Education, Eha-Amufu in South-East Nigeria. Due to the college’s tight academic calendar, we were allowed to meet with the participants once a week. One session was held a week, lasting for 40 minutes. Different issues and topics were discussed during the sessions. In the first session, the researchers spelled out the procedure for group interaction. During this session we highlighted that our group norms included confidentiality, commitment, and mutual respect among participants.
The second session focused on describing the meaning of PIU. The participants, including the researchers, shared the meaning of PIU. This was an opportunity to understand the feelings of others and their experiences. The researchers also explored what needs participants had neglected as a result of excessive internet use. At the end of the session, a home exercise was given to the participants. At this stage, the researchers focused on dealing with basic factors that induce the participants to engage in excessive internet usage.
In session three, the participants were allowed to discuss the problems they encountered in their studies that could be linked with PIU. Some of these problems include inadequate preparation for examinations, late submission of assignments, inadequate concentration in classes, and examination phobia. The researchers exposed participants to cognitive behavioral techniques for possible solutions to the problems identified, such as problem solving, cognitive restructuring, and time management techniques. Other things the researchers trained the participants about were how to identify erroneous thoughts and cognitive errors, enhancing self-worth, controlling anger and assertiveness.55
Homework was given to participants to practice mood monitoring, and time management techniques.
During sessions four and five, the session participants shared knowledge on how to explore alternative activities rather than PIU and how to recognize internet usage patterns and their addiction triggers. This was followed by session six. The participants reviewed the group rules and made oral and written contracts with group members. They promised to make a commitment plan to quit excessive internet usage and committed to doing their assignments. In session seven, the researchers reviewed the practice exercises brought by the participants. Closely after that, they reviewed and made positive reminder cards and encouraged the group to use them in their real life, reducing excessive internet use. Assignment: use positive reminder cards.
Finally, the last session was held. The content was a follow up of the homework/assignment. Significant accomplishments of the group were reviewed. The group participants were thanked for their cooperation. Remind the group participants of the need for confidentiality. Refreshment was offered to the participants at the end the group sessions. The researchers expressed appreciation to the group participants for their commitment and cooperation. The techniques adopted during the treatment included shaping, cognitive restructuring, relaxation technique, systematic desensitization, reinforcement, ignoring technique, mood monitoring, problem-solving, and listening.
After completion of the experiment, both the treatment and the control group completed the post-test assessment. One month after completion of the post-test assessment, the 40 participants from both groups attended a one month follow-up meeting after which they completed the PIUs for the third time (Time 3) at the end of the meeting to ascertain if the probable effect was maintained and sustained by the participants. The maximum attendance was achieved because of active engagement by the research team, who monitored the intervention process. The participants saw them as external bodies monitoring their commitments, believing that they were under watch. Equally, the participants were provided with a hired bus that consistently conveyed them to the treatment venue. The presence of the college teachers/lecturers also enhanced the students’ active participation, as some of the lecturers were also committed to monitor the students’ activities. Given these precautions, no dropouts were recorded during the study. The researchers collated the data from the participants directly after each assessment. This is a blind study in which the researchers did not disclose the identities of the participants to the data analysts to avoid revealing which participants were in the intervention group and which were in the waitlisted group. This was to ensure concealment of information during the study. To ensure there were no missing responses, we engaged three data analysts, each to analyze one set of assessment data e.g., Time 1.
Full text: Click here
Publication 2023
Addictive Behavior Anger ARID1A protein, human Cognition Feelings Human Body Hyposensitization Therapies Mood Phobias Physical Examination Precipitating Factors Reinforcement, Psychological Relaxation Techniques Student Thinking Visually Impaired Persons
Measurements of the responses of cells stably expressing fish T1Rs by calcium imaging were conducted as described previously [24 (link), 26 ] with a slight modification. Cells were seeded in 96‐well plates (Lumox Multiwell 96‐well, Starstedt AG, and Co., Nümbrecht, Germany) at approximately 50 000 cells per well. After 16–22 h, the medium was removed and replaced with assay buffer. Notably, the temperature of 37 °C, which is higher than that of the natural environment for fish, and/or desensitization caused by l‐amino acids in DMEM likely resulted in the degradation or the desensitization of the fish taste receptors. To improve the signal intensity by avoiding these problems, cells were incubated in the assay buffer at 27 °C for 3 h 15 min. After the incubation, cells were loaded with 5 μm fura‐2/AM (Thermo Fisher Scientific) in assay buffer for 30 min at 27 °C. The cells were washed with the assay buffer and incubated in 100 μL of assay buffer for 15 min at room temperature.
The cells were stimulated with l‐amino acids by adding 100 μL of 2× ligands at room temperature. The intensities of fura‐2 fluorescence emissions resulting from excitation at 340 and 380 nm were measured at 510 nm using a computer‐controlled filter exchanger (Lambda 10–3; Sutter Instruments, Novato, CA, USA), CoolSNAP HQ2 charge‐coupled device camera (Photometrics, Tucson, AZ, USA), and inverted fluorescence microscope (IX‐70; Olympus, Tokyo, Japan). The images were recorded at 4‐s intervals and analyzed using metafluor software (Molecular Devices, Sunnyvale, CA, USA). Data were presented in pseudocolor images based on the fluorescence intensity ratio at the two excitation wavelengths (F340/F380).
Full text: Click here
Publication 2023
Amino Acids Biological Assay Buffers Calcium Cells Fishes Fluorescence Fura-2 fura-2-am Hyposensitization Therapies Ligands Medical Devices Microscopy, Fluorescence Taste Buds

Top products related to «Hyposensitization Therapies»

Sourced in United States, United Kingdom, Canada
Clampfit 10 is a software application designed for the analysis of electrophysiological data. It provides tools for data acquisition, visualization, and signal processing.
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
Sourced in United States, Germany, Canada, United Kingdom, China, Australia
PClamp 10 software is a data acquisition and analysis platform for electrophysiology research. It provides tools for recording, analyzing, and visualizing electrical signals from cells and tissues.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States, Germany, United Kingdom, Israel, Canada, Austria, Belgium, Poland, Lao People's Democratic Republic, Japan, China, France, Brazil, New Zealand, Switzerland, Sweden, Australia
GraphPad Prism 5 is a data analysis and graphing software. It provides tools for data organization, statistical analysis, and visual representation of results.
Sourced in United States, France, Canada, Germany, Ireland, Switzerland
Thymoglobulin is a polyclonal antithymocyte globulin (ATG) product developed by Sanofi. It is a sterile, purified, and concentrated immunoglobulin preparation derived from the plasma of horses immunized with human thymocytes. Thymoglobulin is used as an immunosuppressant to prevent and treat acute rejection in organ transplantation.
Sourced in United States, France, Japan, Germany, United Kingdom
The Axopatch 200B is a high-performance patch-clamp amplifier designed for electrophysiology research. It is capable of amplifying and filtering electrical signals from single-cell preparations, providing researchers with a tool to study ion channel and membrane properties.
Sourced in Switzerland, United States, Canada
Simulect is a laboratory equipment product manufactured by Novartis. It is designed for use in scientific research and clinical applications.
Sourced in United States, Canada, United Kingdom, Japan
The Digidata 1440A is a high-performance data acquisition system designed for a variety of electrophysiology applications. It features 16-bit analog-to-digital conversion, multiple sampling rates, and simultaneous acquisition of multiple channels. The Digidata 1440A provides the hardware interface for recording and digitizing electrophysiological signals.
Sourced in United States, United Kingdom, Canada, China, Germany, Japan, Belgium, Israel, Lao People's Democratic Republic, Italy, France, Austria, Sweden, Switzerland, Ireland, Finland
Prism 6 is a data analysis and graphing software developed by GraphPad. It provides tools for curve fitting, statistical analysis, and data visualization.

More about "Hyposensitization Therapies"

Hyposensitization Therapies, also known as Immunotherapy or Allergy Desensitization, are a systematic approach to desensitize the immune system and reduce allergic reactions.
These therapies gradually expose individuals to small, controlled amounts of allergens to build tolerance and mitigate symptoms.
PubCompare.ai, powered by advanced AI algorithms, can help identify the most effective hyposensitization protocols from scientific literature, preprints, and patents, optimizing the treatment process for a smoother and more efficient outcome.
Hyposensitization Therapies are commonly used to address a variety of allergic conditions, such as hay fever (allergic rhinitis), asthma, and food allergies.
By exposing the patient to gradually increasing doses of the offending allergen, the immune system can be trained to become less reactive, leading to a reduction in the severity and frequency of allergic symptoms.
The process of Hyposensitization Therapy often involves the use of specialized software and equipment, such as Clampfit 10 for data analysis, Gonal-F for medication administration, and PClamp 10 for electrophysiological recordings.
Additionally, tools like MATLAB and GraphPad Prism 5 may be utilized for data visualization and statistical analysis.
In some cases, Hyposensitization Therapies may be combined with other immunosuppressive agents, such as Thymoglobulin, to enhance the effectiveness of the treatment.
The Axopatch 200B amplifier, Simulect, and Digidata 1440A may also play a role in the monitoring and administration of these therapies.
Prism 6 can be a valuable tool for researchers and clinicians in the field of Hyposensitization Therapies, as it allows for the efficient analysis and visualization of data collected during the treatment process.
By leveraging the insights gained from MeSH term descriptions and advanced AI-powered tools like PubCompare.ai, healthcare professionals can optimize the Hyposensitization Therapy process, leading to improved outcomes for patients and a smoother, more efficient treatment experience.